Natural Capsules Ltd (NATCAPSUQ) — shareholding pattern, promoter holding, financials and share price
About Natural Capsules Ltd (NATCAPSUQ)
Natural Capsules Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as NATCAPSUQ and on the BSE under scrip code 524654. Its ISIN is INE936B01015.
Incorporated in 1993, Natural Capsules manufactures Capsules and Steroidal APIs and their Intermediates and Derivatives [1]
Natural Capsules Limited is an established Indian manufacturer of hard capsule shells (gelatin and HPMC), a pioneer of vegetarian capsules in India, and is expanding into steroidal API manufacturing through its subsidiary Natural Biogenex Private Limited, operating two manufacturing plants in Bengaluru and Puducherry and a greenfield API site in Tumkur.
Financials show acute short‑term stress: Q3FY26 consolidated revenue of ₹37.75 crore (down 14% YoY) and a PAT loss of ₹7.12 crore, driven by a temporary regulatory shutdown at the Puducherry unit, delayed API fermentation scale up and higher depreciation and finance costs, all of which weighed on margins and cash generation.
Listed peers in Pharmaceuticals: Panchsheel Organics Ltd, Auro Laboratories Ltd, Quest Laboratories Ltd, Kimia Biosciences Ltd, Alpa Laboratories Ltd, Smruthi Organics Ltd.
Valuation & Returns
10 Jul 2026At ₹141.35 a share on 10 Jul 2026, Natural Capsules Ltd (NATCAPSUQ) was valued at a price-to-earnings ratio of -7.06x against an industry P/E of 36.41x and a price-to-book of 0.63x on a book value of ₹223.74 per share as of Mar 2025. Solomo computes return on equity of -10.59% and return on capital employed of -5.02% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -7.06x
- Industry P/E
- 36.41x
- P/B
- 0.63x
- EPS (TTM)
- ₹-23.7
- Book value / share
- ₹223.74
- ROE
- -10.59%
- ROCE
- -5.02%
- ROA
- -5.88%
- Debt / equity
- 0.45x
- Dividend yield
- 0%
- EBITDA margin
- 0.09%
- 52-week range
- ₹137.5 – ₹296.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Natural Capsules Ltd (NATCAPSUQ) reported revenue of ₹187 crore, net profit of ₹-25 crore and earnings per share of ₹-16.44. That compares with revenue of ₹169 crore and net profit of ₹1 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹58.45 crore and net profit ₹-4.98 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 135 | 170 | 155 | 169 | 187 |
| Net profit (₹ cr) | 14 | 18 | 6 | 1 | -25 |
| EPS (₹) | 14.96 | 20.02 | 5.95 | 0.6 | -16.44 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 11.70% | 22.23% | 7.53% | 8.87% |
| Profit growth | 4.97% | 50.91% | -21.65% | -88.83% |
| Stock price CAGR | 5% | 0% | -27% | -35% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 50.92% of Natural Capsules Ltd (NATCAPSUQ) (down 0.12 pp QoQ). Market capitalisation was ₹147 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2002.
Largest disclosed public shareholders in Jun 2026: SANGEETHA S 3.14%, HUF 2.95%, TARINIKA MANAGEMENT LLP 2.74%, ANURAG SINGHI 1.69%, PCG FINVEST PRIVATE LIMITED 1.6%, VIVOG COMMERCIAL LIMITED 1.43%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 50.92% | - | - | - | 49.08% |
| Mar 2026 | 51.04% | - | 0% | 0% | 48.96% |
| Dec 2025 | 51.26% | - | 0% | 0% | 48.74% |
| Sep 2025 | 51.26% | - | 0% | 0% | 48.74% |
| Jun 2025 | 51.26% | - | - | - | 48.74% |
| Mar 2025 | 51.21% | - | - | - | 48.79% |
| Dec 2024 | 51.14% | - | - | - | 48.86% |
| Sep 2024 | 51.6% | - | - | 0% | 48.4% |